drugset
drugset / Trial / NCT05127122

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS

NCT05127122 ↗

Phase 1/2 Withdrawn Direct Biologics, LLC
RandomizedCrossoverQuadruple-blindTreatment

Summary

To evaluate the safety and efficacy of intravenous(IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles(EV), ExoFlo, as treatment for Acute Respiratory Distress Syndrome.

Timeline

Start
2024-12
Primary completion
2024-12
Completion
2024-12

Outcome

Outcome not reported

Stopped: “Change in development plan”

Drugs

EvaluationDrugModalityDoseRoute
Subject ExoFlo Other / unclassified 10 ml Intravenous
Subject ExoFlo Other / unclassified 15 ml Intravenous

Indications

acute respiratory distress syndrome